FluoGuide AS
96X
Company Profile
Business description
FluoGuide AS is a late-stage clinical biotechnology company focused on precision cancer surgery. Its flagship product, FG001, is a uPAR-targeted fluorescent imaging agent designed to help visualize cancer tissue during surgical procedures. The company is developing FG001 for use across multiple cancer indications.
Contact
Titanhus, Titangade 9-13
CopenhagenDK-2200
DNKT: +45 31226660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.90 | 54.00 | -0.60% |
| CAC 40 | 8,177.89 | 157.58 | 1.96% |
| DAX 40 | 26,437.67 | 573.05 | 2.22% |
| Dow JONES (US) | 53,356.12 | 1,569.40 | 3.03% |
| FTSE 100 | 10,829.21 | 190.78 | 1.79% |
| HKSE | 23,919.50 | 393.53 | 1.67% |
| NASDAQ | 25,736.51 | 364.50 | 1.44% |
| Nikkei 225 | 62,188.63 | 893.23 | -1.42% |
| NZX 50 Index | 14,011.28 | 227.83 | 1.65% |
| S&P 500 | 7,688.62 | 119.70 | 1.58% |
| S&P/ASX 200 | 8,834.50 | 52.30 | -0.59% |
| SSE Composite Index | 3,686.17 | 78.07 | 2.16% |